Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apomorphine Nasal Powder for Parkinson's Disease "Off" Periods
NCT00346827Phase 3Completed
- Sponsor
- Britannia Pharmaceuticals
- Start
- Jul 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (3 arms), sponsored by Britannia Pharmaceuticals. Primary endpoint: Safety and Tolerability of Repeated Dosing. Started Jul 2006; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00346827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346827.